PIH Russia inaugurates WHO Collaborating Center in Novosibirsk.

Kazakh physicians focus on addressing an epidemic of multidrug-resistant tuberculosis.

The Lancet reports on PIH partnership working to tackle tuberculosis in Chiapas, Mexico.

Teodulfo Blaas' MDR-TB diagnosis meant that he had to give up his job as a laborer. But thanks in part to SES, he's now a successful business owner.

View a slideshow of images depicting PIH's work to fight tuberculosis at our sites around the world.

In recognition of its success in combating MDR-TB and other global health issues, Socios En Salud (PIH's partner organization in Peru) recently accepted two distinguished awards

PIH's 15th annual Thomas J. White Symposium focused on the theme "Pushing boundaries: past, present, and future." The program featured a panel of HIV patients who shared their stories of being provided with life-saving antiretroviral drugs. Another panel featured activists who have used the PIH model and philosophy of social justice to create their own programs to provide healthcare to the poor and inspire the next generation of social justice activists. View these panels as well as speeches from PIH co-founders Paul Farmer and Ophelia Dahl.

Extensively drug-resistant tuberculosis (XDR-TB) is curable with intensive and specialized care conclude two recent studies published in the New England Journal of Medicine (NEJM) and The Lancet. Researchers found that fully 60 percent of the patients enrolled in the studies with XDR-TB were successfully treated and cured.

In the small mountainous country of Lesotho, patients infected with multidrug-resistant tuberculosis (MDR-TB) faced almost certain death just one year ago. Today they and their families have reason to hope for a better prognosis. Last July, the first patients enrolled in Lesotho

Every since she was a child growing up in Haiti, Marie Myrléne St. Vil Marius has wanted to dedicate her life “to people who have nothing and are in need.”